Antimycobacterial Drugs Flashcards
Treatment: M. tuberculosis
Rifampin
Isoniazid
Pyrazinamide
Ethambutol
(RIPE)
Treatment: M. leprae
(lepromatous form)
Long-term Dapson + Rifampin
+ Clofazimine
Prophylaxis: M. avium-intracellulare
Azithromycin
Rifabutin
Clinical use: Ethambutol
- Mycobacterium tuberculosis
Treatment: M. leprae
(tuberculoid form)
Long-term Dapson + Rifampin
Clinical use: Rifamycins
Rifampin
Rifabutin
- Mycobacterium tuberculosis
- Leprosy: Delays resistance to Dapsone
- Prophylaxis:
- N. meningitidis (meningitis)
- Haemophilus influenza type B (meningitis)
- Rifabutin favored over Rifampin in HIV due to less P-450 stimulation (reduces protease inhibitor concentrations)
Mechanism: Rifamycins
Rifampin
Rifabutin
RNA synthesis inhibitor:
Inhibit DNA-dependent RNA polymerase → inhibiting bacterial RNA synthesis
Mechanism: Isoniazid (INH)
- Decrease synthesis of mycolic acids
- Bacterial catalase-peroxidase (encoded by KatG) needed to convert INH to active metabolite
Mechanism: Pyrazinamide
Uncertain
Prodrug that is converted to the active compound pyrazinoic acid
Works best at acidic pH (e.g., host phagolysosomes)
Adverse effects: Rifamycins
Rifampin
Rifabutin
- Minor hepatotoxicity
- Drug interactions (P-450 inducer)
- Orange body fluids (nonhazardous)
Resistance: Isoniazid
Mutations leading to underexpression of KatG
(encodes bacterial catalase peroxidase)
Clinical use: Streptomycin
- Mycobacterium tuberculosis (2nd line)
Prophylaxis: M. tuberculosis
Isoniazid (INH)
Adverse effects: Streptomycin
- Nephrotoxicity
- Tinnitus
- Vertigo
- Ataxia
Adverse effects: Pyrazinamide
- Hyperuricemia
- Hepatotoxicity